AstraZeneca PLC (AZNCF)

Market Cap	210.83B
Revenue (ttm)	51.21B
Net Income (ttm)	6.50B
Shares Out	n/a
EPS (ttm)	4.15
PE Ratio	32.46
Forward PE	n/a
Dividend	1.00 (0.74%)
Ex-Dividend Date	Aug 8, 2024

Volume	1,000
Average Volume	3,387
Open	135.00
Previous Close	135.79
Day's Range	135.00 - 138.06
52-Week Range	118.16 - 175.00
Beta	0.18
RSI	58.51
Earnings Date	Feb 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 89,900
• Stock Exchange: OTCMKTS
• Ticker Symbol: AZNCF

Financial Performance

In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.